| 3.92 0.29 (7.99%) | 03-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.34 |
1-year : | 6.24 |
| Resists | First : | 4.57 |
Second : | 5.34 |
| Pivot price | 3.47 |
|||
| Supports | First : | 3.46 |
Second : | 2.77 |
| MAs | MA(5) : | 3.81  |
MA(20) : | 3.37 |
| MA(100) : | 2.35 |
MA(250) : | 2.06 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 53.5 |
D(3) : | 55.6 |
| RSI | RSI(14): 63.4 |
|||
| 52-week | High : | 4.57 | Low : | 1.29 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ADAG ] has closed below upper band by 25.0%. Bollinger Bands are 142.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4 - 4.02 | 4.02 - 4.04 |
| Low: | 3.4 - 3.43 | 3.43 - 3.45 |
| Close: | 3.88 - 3.92 | 3.92 - 3.96 |
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Wed, 18 Mar 2026
Adagene (NASDAQ: ADAG) CSO reports options and warrant stakes - Stock Titan
Wed, 18 Mar 2026
Adagene (ADAG) CFO Tam Man Kin details shares, RSUs and options - Stock Titan
Wed, 18 Mar 2026
Adagene (NASDAQ: ADAG) director details stock option holdings - Stock Titan
Wed, 18 Mar 2026
Adagene (ADAG) finance leader lists options, RSUs and shares - Stock Titan
Wed, 18 Mar 2026
Adagene (NASDAQ: ADAG) director details 70,000-share option position in Form 3 - Stock Titan
Wed, 18 Mar 2026
Adagene (NASDAQ: ADAG) CMO discloses stock options, RSUs and shares - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 3.294e+007 (%) |
| Held by Institutions | 15.5 (%) |
| Shares Short | 16 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.277e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -32 % |
| Return on Assets (ttm) | 283.6 % |
| Return on Equity (ttm) | -24.9 % |
| Qtrly Rev. Growth | 103200 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -80.08 |
| EBITDA (p.s.) | 130633 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 3.87 |
| Dividend | 0 |
| Forward Dividend | 47430 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|